Whalesbook
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Global Generics Segment (~83% of revenues in FY22)Co. offers 400+ high-quality generic drugs, keeping costs reasonable by leveraging its integrated operations. The company benefits from its expertise in active ingredients, product development skills, a keen understanding of regulations and intellectual property rights & streamlined supply chain.[1]Top revenue contributors of the segment are nervous system drugs (14%), gastrointestinal (13%) & anti-infective (10%)[2]In FY22, co. filed 7 new ANDA’s with US FDA[3]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1818.30 | 37.79 | 436271.08 | 0.88 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.61 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6469.00 | 69.11 | 171731.62 | 0.46 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.14 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 3795.70 | 59.29 | 128457.97 | 0.84 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 15.20 | 13.26 | 0.33 |
| 4. | Cipla | 1521.00 | 22.58 | 122862.00 | 0.85 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.73 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1277.60 | 19.75 | 106631.20 | 0.63 | 387.30 | -79.42 | 4618.60 | -31.03 | 25.75 | 23006.00 | 30.22 | 5398.60 | 387.30 | 3.38 | 15.68 | 0.13 |
| 6. | Lupin | 2092.00 | 22.10 | 95554.65 | 0.57 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 4.87 | 12.41 | 0.32 |
| 7. | Zydus Lifesci. | 935.75 | 18.72 | 94158.35 | 1.18 | 1238.60 | 40.92 | 6123.20 | 16.92 | 24.31 | 24493.90 | 31.10 | 5029.35 | 1283.60 | 3.72 | 14.64 | 0.38 |
| – | Median: 148 Co. | 409.77 | 31.82 | 1710.38 | 0.12 | 12.57 | 12.32 | 152.64 | 10.54 | 14.85 | 582.87 | 15.93 | 44.55 | 13.49 | 3.2 | 8.39 | 0.22 |
Standalone figures in ₹ crores
| Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 4,880 | 3,898 | 4,554 | 5,437 | 4,839 | 4,103 | 5,105 | 5,841 | 6,696 | 5,015 | 5,563 | 7,810 | 4,619 |
Expenses | 3,078 | 3,222 | 3,493 | 3,210 | 3,210 | 3,447 | 3,726 | 3,888 | 3,975 | 3,823 | 4,120 | 3,972 | 4,138 |
Operating Profit | 1,803 | 675 | 1,061 | 2,228 | 1,629 | 656 | 1,379 | 1,953 | 2,722 | 1,192 | 1,443 | 3,837 | 480 |
Other Income | 118 | 51 | 115 | 234 | 223 | 228 | 213 | 218 | 208 | 235 | 414 | 398 | 364 |
Profit before tax | 1,693 | 485 | 937 | 2,220 | 1,601 | 632 | 1,339 | 1,914 | 2,641 | 1,119 | 1,562 | 3,936 | 516 |
Tax % | 34% | 33% | 28% | 26% | 25% | 25% | 23% | 26% | 29% | 24% | 23% | 25% | 25% |
Net Profit | 1,116 | 325 | 672 | 1,639 | 1,193 | 475 | 1,035 | 1,417 | 1,882 | 849 | 1,201 | 2,961 | 387 |
EPS in Rs | 13.41 | 3.90 | 8.08 | 19.69 | 14.30 | 5.70 | 12.41 | 16.99 | 22.56 | 10.18 | 14.39 | 35.48 | 4.64 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 9,728 | 10,011 | 10,292 | 9,720 | 9,359 | 10,626 | 11,850 | 13,349 | 14,405 | 16,962 | 19,484 | 23,115 | 23,006 |
Expenses | 6,950 | 7,608 | 8,219 | 7,899 | 7,990 | 8,290 | 8,967 | 10,212 | 11,803 | 12,724 | 13,557 | 15,691 | 16,053 |
Operating Profit | 2,778 | 2,403 | 2,073 | 1,820 | 1,370 | 2,336 | 2,883 | 3,137 | 2,602 | 4,238 | 5,926 | 7,425 | 6,953 |
Other Income | 135 | 211 | 317 | 516 | 164 | 202 | 730 | 801 | 474 | 568 | 862 | 961 | 1,412 |
Interest | 78 | 64 | 64 | 57 | 63 | 57 | 48 | 47 | 38 | 17 | 22 | 110 | 127 |
Depreciation | 380 | 490 | 650 | 735 | 774 | 781 | 789 | 835 | 814 | 923 | 976 | 1,039 | 1,104 |
Profit before tax | 2,454 | 2,060 | 1,677 | 1,544 | 697 | 1,701 | 2,776 | 3,056 | 2,224 | 3,866 | 5,791 | 7,236 | 7,134 |
Net Profit | 1,933 | 1,679 | 1,374 | 1,384 | 567 | 1,277 | 2,938 | 2,186 | 1,623 | 2,613 | 4,342 | 5,349 | 5,399 |
EPS in Rs | 22.73 | 19.71 | 16.11 | 16.70 | 6.83 | 15.38 | 35.36 | 26.29 | 19.51 | 31.38 | 52.06 | 64.11 | 64.69 |
Dividend Payout % | 16% | 20% | 25% | 24% | 59% | 26% | 14% | 19% | 31% | 26% | 15% | 12% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 85 | 85 | 85 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
Reserves | 9,244 | 10,549 | 11,993 | 11,518 | 11,725 | 12,601 | 15,109 | 16,900 | 18,253 | 20,391 | 24,157 | 28,773 | 31,429 |
Borrowings | 2,666 | 3,126 | 3,085 | 2,355 | 2,589 | 1,065 | 1,457 | 1,214 | 2,205 | 51 | 793 | 3,493 | 3,979 |
Other Liabilities | 2,513 | 2,696 | 2,422 | 2,491 | 2,704 | 2,499 | 2,827 | 3,431 | 3,954 | 4,850 | 5,326 | 5,941 | 7,099 |
Total Liabilities | 14,508 | 16,456 | 17,585 | 16,447 | 17,100 | 16,248 | 19,476 | 21,630 | 24,496 | 25,375 | 30,359 | 38,291 | 42,591 |
Fixed Assets | 2,748 | 3,249 | 4,438 | 4,842 | 4,717 | 4,683 | 4,434 | 5,844 | 6,150 | 7,195 | 7,589 | 8,232 | 9,813 |
Gross Block | 4,900 | 5,816 | 7,580 | 8,675 | 9,224 | 9,774 | 10,216 | 12,345 | 13,349 | 15,137 | 16,297 | 17,715 | – |
Accumulated Depreciation | 2,151 | 2,566 | 3,142 | 3,833 | 4,506 | 5,091 | 5,782 | 6,501 | 7,199 | 7,941 | 8,708 | 9,482 | – |
CWIP | 576 | 488 | 616 | 540 | 675 | 400 | 412 | 901 | 1,200 | 924 | 1,211 | 2,197 | 1,706 |
Investments | 2,806 | 3,862 | 5,076 | 3,102 | 3,636 | 3,934 | 5,486 | 4,649 | 4,937 | 7,440 | 7,321 | 13,194 | 14,416 |
Other Assets | 8,377 | 8,856 | 7,455 | 7,963 | 8,072 | 7,231 | 9,145 | 10,235 | 12,208 | 9,815 | 14,239 | 14,668 | 16,655 |
Total Assets | 14,508 | 16,456 | 17,585 | 16,447 | 17,100 | 16,248 | 19,476 | 21,630 | 24,496 | 25,375 | 30,359 | 38,291 | 42,591 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 906 | 1,786 | 2,747 | 1,016 | 1,539 | 2,762 | 1,839 | 3,514 | 1,339 | 5,053 | 3,450 | 4,225 |
Cash from Investing Activity | -874 | -2,031 | -1,919 | 1,430 | -1,180 | -546 | -1,689 | -1,454 | -1,990 | -3,403 | -3,429 | -5,697 |
Cash from Financing Activity | 28 | 189 | -693 | -2,582 | -304 | -2,223 | -224 | -794 | 506 | -2,697 | 68 | 1,591 |
Net Cash Flow | 60 | -56 | 135 | -135 | 54 | -8 | -74 | 1,266 | -146 | -1,047 | 89 | 118 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 171 | 172 | 138 | 165 | 164 | 128 | 143 | 112 | 125 | 92 | 87 | 94 |
Inventory Days | 233 | 223 | 234 | 256 | 258 | 242 | 224 | 250 | 242 | 219 | 291 | 275 |
Days Payable | 123 | 93 | 99 | 110 | 147 | 124 | 109 | 118 | 121 | 127 | 148 | 120 |
Cash Conversion Cycle | 281 | 302 | 273 | 311 | 274 | 246 | 257 | 243 | 247 | 184 | 230 | 250 |
Working Capital Days | 115 | 99 | 82 | 112 | 98 | 125 | 116 | 95 | 89 | 95 | 130 | 63 |
ROCE % | 23% | 16% | 12% | 11% | 5% | 12% | 19% | 15% | 12% | 19% | 25% | 26% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Oct 2025
Jul 2025
May 2025
Jan 2025
Nov 2024
Aug 2024
Jul 2024
May 2024
Feb 2024
Nov 2023
Jul 2023
May 2023
Jan 2023
Nov 2022
Jun 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
May 2020
Jan 2020
Oct 2019
Jul 2019
Apr 2017
Oct 2016
Jul 2016
Apr 2016
Nov 2015
